Zymergen, a developer of molecular technology for product and material discovery, has raised over $400 million in a Series C funding led by SoftBank Vision Fund. New investors Goldman Sachs and Hanwha Asset Management joined existing investors DCVC, True Ventures, Two Sigma Ventures, DFJ and Innovation Endeavors in the round.

The infusion of capital will allow the company to accelerate its growth, expand its platform and begin commercializing products from its proprietary portfolio.  Zymergen’s commercial success and continued innovation will "catalyze industrial progress across agriculture, chemicals and materials, pharmaceuticals, and more."

The Gunderson Dettmer deal team representing Zymergen was led by partners David Young and Jared Grauer and associates Stephanie Lane and William Haynes.

For further details, Zymergen’s press release can be found here.